CTB
NAVB

Country Trust Bank’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Country Trust Bank’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$2 – 310
2023
Q1 		$2 Buy
+7
New +$2 ﹤0.01% 297

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Country Trust Bank's NAVB Position: Q2 2023 in Review

Country Trust Bank sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 7 shares — an estimated $2 sold.

Country Trust Bank first reported a position in NAVB in Q1 2023 and held it in 1 quarter. The position peaked at $2 in Q1 2023. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Country Trust Bank reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Country Trust Bank sold 7 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $2.
  • Country Trust Bank first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2023 and held it in 1 quarter.
  • Country Trust Bank's Navidea Biopharmaceuticals Inc. position peaked at $2 in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Country Trust Bank's 13F filing for Q2 2023, filed 12 Jul 2023.